Bone Biologics Expands Trial Sites
Bone Biologics said six hospital sites in Australia are now under agreement for its first-in-human pilot trial of NB1, doubling the number of participating centers and strengthening its expectation of completing enrollment by year-end 2026. The pilot study tests the rhNELL-1-based bone graft in up to 30 adults with degenerative disc disease undergoing transforaminal lumbar interbody fusion, with fusion success at 12 and 24 months and Oswestry Disability Index change as primary clinical endpoints.
Key figures
- Drug Name
- NB1
- Phase Of Trial
- first-in-human pilot
- Cash runway
- through the second quarter of 2027
- Planned subjects
- up to 30 adult subjects
- Enrollment target
- year-end 2026
- Primary endpoints
- fusion success at 12 and 24 months; change from baseline in Oswestry Disability Index
- Trial sites change
- doubles the number of participating centers
- Trial sites australia
- 6
- Rh NELL1 shelf life months
- 32
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.